Literature DB >> 16932734

Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis.

Lars Klareskog1, Leonid Padyukov, Johnny Lorentzen, Lars Alfredsson.   

Abstract

Rheumatoid arthritis (RA) is a complex disease in which environmental agents are thought to interact with genetic factors that influence susceptibility. This interaction triggers immunologic events that eventually result in the clinical signs of arthritis. Knowledge of the chain of etiological events that lead to the development of RA is incomplete. In this review, we describe the experimental approaches that are used to address the issue of gene-environment interactions in the etiology of RA, and discuss relevant examples of such interactions. We focus on how smoking, the best-known environmental risk factor for RA, interacts with HLA-DR shared epitope genes, the main genetic risk factors for RA, and result in a high risk of RA in individuals exposed to both of these risk factors. From these and other related findings, we can begin to define the distinct environmental risk factors (such as smoking) that in certain genetic contexts (for example, the presence of HLA-DR shared epitope alleles) can trigger immune reactions (such as autoantibodies to citrullinated peptides) many years before onset of RA, and consider how these immune reactions might contribute to clinical symptoms in a subset of affected patients. Increased knowledge about these and other events involved in the development of RA should enable the design of new tools for suppressing RA pathogenesis before the onset of disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932734     DOI: 10.1038/ncprheum0249

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN: 1745-8382


  61 in total

1.  GEIRA: gene-environment and gene-gene interaction research application.

Authors:  Bo Ding; Henrik Källberg; Lars Klareskog; Leonid Padyukov; Lars Alfredsson
Journal:  Eur J Epidemiol       Date:  2011-04-26       Impact factor: 8.082

2.  Patterns of background factors related to early RA patients' conceptions of the cause of their disease.

Authors:  Ulrika Bergsten; Stefan Bergman; Bengt Fridlund; Lars Alfredsson; Anita Berglund; Barbro Arvidsson; Ingemar F Petersson
Journal:  Clin Rheumatol       Date:  2010-08-24       Impact factor: 2.980

Review 3.  Human Leukocyte Antigen-Disease Associations in Rheumatoid Arthritis.

Authors:  Vincent van Drongelen; Joseph Holoshitz
Journal:  Rheum Dis Clin North Am       Date:  2017-08       Impact factor: 2.670

4.  Detecting gene-environment interactions using a combined case-only and case-control approach.

Authors:  Dalin Li; David V Conti
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

Review 5.  Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?

Authors:  A M Mohamed Thoufic Ali; S Vino
Journal:  Rheumatol Int       Date:  2016-09-16       Impact factor: 2.631

Review 6.  Cellular and molecular perspectives in rheumatoid arthritis.

Authors:  Douglas J Veale; Carl Orr; Ursula Fearon
Journal:  Semin Immunopathol       Date:  2017-05-15       Impact factor: 9.623

7.  Cellular and humoral immunity in arthritis are profoundly influenced by the interaction between cigarette smoke effects and host HLA-DR and DQ genes.

Authors:  Robert Vassallo; David Luckey; Marshall Behrens; Benjamin Madden; Harvinder Luthra; Chella David; Veena Taneja
Journal:  Clin Immunol       Date:  2014-02-14       Impact factor: 3.969

8.  Study of cannabinoid receptor 2 Q63R gene polymorphism in Lebanese patients with rheumatoid arthritis.

Authors:  Morouj Ismail; Ghada Khawaja
Journal:  Clin Rheumatol       Date:  2018-07-21       Impact factor: 2.980

Review 9.  Vascular effects of biologic agents in RA and spondyloarthropathies.

Authors:  Zoltán Szekanecz; György Kerekes; Pál Soltész
Journal:  Nat Rev Rheumatol       Date:  2009-11-10       Impact factor: 20.543

10.  Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis.

Authors:  José Félix Restrepo; Inmaculada del Rincón; Daniel F Battafarano; Roy W Haas; Merced Doria; Agustín Escalante
Journal:  Clin Rheumatol       Date:  2015-08-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.